Imbruvica’s revenue trends
AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.
In fiscal 2017, Imbruvica reported revenue of $2.6 billion, which reflected ~40.5% YoY growth. In 2017, in US and international markets, Imbruvica generated revenue of $2.1 billion and $429 million, respectively, representing ~35.8% and 70% YoY growth.
In December 2017, AbbVie announced the long-term follow-up data from two Phase 2 studies on relapsed/refractory mantle cell lymphoma in patients receiving Imbruvica. In a press release, AbbVie reported that, at three years, 45% of patients achieved overall survival and 26% achieved disease progression-free survival.
In December 2017, AbbVie released three-year follow-up data from its RESONATE-2 trial, which demonstrated that previously untreated individuals with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma showed consistent improvement with Imbruvica therapy. In the clinical trial, patients on Imbruvica demonstrated progression-free survival of 85%, compared with 28% for patients on chlorambucil.
According to the American Cancer Society, there are ~115,000 individuals with CLL in the United States, with 19,000 newly diagnosed patients each year. In the CLL drug market, Imbruvica competes with Roche’s (RHHBY) Gazyva, Teva Pharmaceutical’s (TEVA) Treanda, and Gilead Sciences’ (GILD) Zydelig.